Reviva Pharmaceuticals Q3 net loss narrows
I'm PortAI, I can summarize articles.
Reviva Pharmaceuticals reported a Q3 net loss of $4 million, an improvement from last year's $8.4 million loss. The company plans a pre-NDA meeting with the FDA for brilaroxazine in Q4 2025 and received a European patent for brilaroxazine in pulmonary fibrosis. They raised $9 million through a public equity offering. Analysts rate the stock as a "buy," with a median 12-month price target of $3.00, significantly above the current price.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments